About Cern

Science-driven innovation for
women's health.

Cern Corporation is a women’s health medical device company developing a safe,
effective, low-level visible-light spectrum (non-UV), non-hormonal platform for both
yeast and bacterial vaginal infections. We integrate microbicidal light, microbiology,
clinical medicine, and device engineering to build non-drug alternatives where none
currently exist.

About Cern

To develop clinically rigorous, light- based medical technologies that provide women a safe, effective, non- drug alternative for yeast & bacterial vaginal infections.

Vision

To establish light-based device therapy as a new standard of care in vaginal health and build the defining platform company in this emerging category.

Leadership Team

Science built for women.

Cern was founded with a singular purpose: to build a safe, effective, non-drug alternative for the
millions of women failed by current vaginal infection treatments. The development that has taken
Cern from concept to IRB-approved human clinical evaluation is driven by a core team of
accomplished women researchers, clinicians, and engineers.

Melanie Santos, MD,
FACOG, FPMRS

Chief Medical Officer

Urogynecology and pelvic reconstructive surgery specialist with 17+ years of clinical experience… Read More

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Hyunsook Park, PhD

Director, Microbiology

Professor of Microbiology at Cal State LA with 20+ years studying Candida albicans and vaginal microbial pathogenesis…. Read More

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Trisha Parikh, PharmD/MBA

Pharmacology Advisor

Clinical pharmacist and strategic leader with over 13 years of expertise in improving patient outcomes across the healthcare spectrum…… Read More

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Track Record

What this team has achieved.

Antimicrobial Resistance

Helping reduce antimicrobial resistance by decreasing antibiotic use.

Addressing Drug-Resistant Vaginal Infections

Demonstrated efficacy against drug-resistant Candida strains with no equivalent in current pharmacologic therapy

Advancing Through Clinical Development

Advanced from concept through IRB approval into human clinical evaluation

Protecting Beneficial Vaginal Flora

Established the ability to preserve Lactobacillus crispatus — first light-based device to demonstrate a microbiome-protective profile

Protected by a Growing Patent Portfolio

Built a strong IP position with multiple issued patents